Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
Very favourable analyst view
Very low or no dividends
Risk / Profitability
Risk: High
Profitability: Favourable
About
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of...
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
Very favourable analyst view
Very low or no dividends
$ 0.4
About
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of...
